Skip to content

Search

Evaluating the impact of the ‘Blow, Breathe, Cough’ health promotion intervention in resolving otitis media with effusion in children: An adaptive randomized-controlled trial protocol

Otitis media with effusion (OME) affects hearing, speech development, and quality of life (QoL) in children. The 'Blow, Breathe, Cough' (BBC) intervention promotes nasal, respiratory, and middle ear clearance through nose blowing, deep breathing, coughing, and hand hygiene. It shows promise in resolving OME but lacks randomized-controlled trial (RCT) evaluation. This paper presents a RCT protocol evaluating BBC's effect on OME resolution, hearing, speech, and QoL in children aged two to seven years.

A systems biology approach to determining the risk for development of otitis media

Peter Ruth Elke Richmond Thornton Seppanen MBBS MRCP(UK) FRACP PhD BSc PhD Head, Vaccine Trials Group Co-head, Bacterial Respiratory Infectious

Dornase alfa as an adjunct therapy to treat chronic ear infections

Chris Glenn Lea-Ann Peter Ruth Brennan-Jones Pearson Kirkham Richmond Thornton PhD BA (Education) PhD Candidate PhD MBBS MRCP(UK) FRACP PhD Head, Ear

Evaluation of a bacterial therapy for prevention of respiratory infection including influenza and otitis media

Deborah Lea-Ann Peter Ruth Strickland Kirkham Richmond Thornton PhD PhD MBBS MRCP(UK) FRACP PhD Head, Pregnancy and Early Life Immunology Co-Head,

Microbiological and immunological factors predicting surgical outcomes for chronic otitis media

Lea-Ann Peter Ruth Kirkham Richmond Thornton PhD MBBS MRCP(UK) FRACP PhD Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,

Pathogens on the rise: is impaired immunity the cause of chronic ear and chest infections?

Ruth Elke Peter Thornton Seppanen Richmond PhD BSc PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Program

ISOM 2023 research Panel 4 - Diagnostics and microbiology of otitis media

To identify and review key research advances from the literature published between 2019 and 2023 on the diagnosis and microbiology of otitis media (OM) including acute otitis media (AOM), recurrent AOM (rAOM), otitis media with effusion (OME), chronic suppurative otitis media (CSOM) and AOM complications (mastoiditis). 

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol

Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended. 

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.